DDInter904 DDInter1376
An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Idarubicin {u} (Compound) resembles {v} (Compound) Valrubicin
Idarubicin {u} (Compound) treats {v} (Disease) breast cancer
Idarubicin {u} (Compound) binds {v} (Gene) CYP2C9
Idarubicin {u} (Compound) upregulates {v} (Gene) MEGF8
Idarubicin {u} (Compound) is included by {v} (Pharmacologic Class) Topoisomerase Inhibitors
Idarubicin {u} (Compound) downregulates {v} (Gene) CBR3
Idarubicin {u} (Compound) causes {v} (Side Effect) Haemorrhage
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Cinoxacin
Idarubicin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Delafloxacin
Idarubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Triclabendazole
Idarubicin (Compound) resembles Valrubicin (Compound)
Idarubicin (Compound) treats breast cancer (Disease)
Idarubicin (Compound) binds CYP2C9 (Gene)
Idarubicin (Compound) upregulates MEGF8 (Gene)
Idarubicin (Compound) is included by Topoisomerase Inhibitors (Pharmacologic Class)
Idarubicin (Compound) downregulates CBR3 (Gene)
Idarubicin (Compound) causes Haemorrhage (Side Effect)
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Cinoxacin
Idarubicin may cause a minor interaction that can limit clinical effects when taken with Delafloxacin
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole